Integra LifeSciences names Dr. Raymond Turner as chief medical officer

PRINCETON, N.J. - Integra LifeSciences Holdings Corporation (NASDAQ:IART), a $1.1 billion medical technology company with annual revenues of $1.62 billion, appointed Dr. Raymond Turner as corporate vice president and chief medical officer, the company announced Monday. According to InvestingPro analysis, the company maintains healthy gross margins of nearly 58% despite current market challenges.

Dr. Turner, a board-certified endovascular neurosurgeon with more than 20 years of surgical practice, will lead worldwide medical affairs and clinical development activities including clinical research, trial operations, evidence generation, medical safety and communications.

Prior to joining Integra, Dr. Turner served as chief medical officer for Siemens Endovascular Robotics at Siemens Healthineers and previously worked as a medical director for Cerenovus, a Johnson & Johnson MedTech company.

He also served as program director of the neurosurgery residency program and chief of neuroscience at the Medical University of South Carolina.

Dr. Turner will continue his clinical practice while serving in his new role at Integra. He currently practices at Intermountain Health in Billings, Montana, and serves as an examiner for the American Board of Neurological Surgery.

"His proven leadership and passion for advancing safety and quality will help us continue to deliver innovative solutions," said Mojdeh Poul, president and chief executive officer of Integra LifeSciences, in a press release statement. InvestingPro data shows the company is currently trading below its Fair Value, with analysts expecting net income growth in the coming year. Investors can access detailed financial analysis and 8 additional ProTips through InvestingPro’s comprehensive research reports.

Dr. Turner completed his undergraduate degree in biology at Sacred Heart University, obtained his medical degree at Karol Marcinkowski University of Medical Sciences in Poland, and completed his residency and fellowship at the Cleveland Clinic. He has authored more than 150 peer-reviewed publications and participated in over 70 research studies. The company is scheduled to report its next earnings on October 29, 2025, which will provide investors with crucial updates on its strategic initiatives under the new leadership.

In other recent news, Integra LifeSciences reported its second-quarter 2025 earnings, surpassing expectations with an adjusted earnings per share (EPS) of $0.45, slightly above the consensus forecast of $0.44. The company also achieved stronger-than-expected revenue, reaching $415.6 million compared to the anticipated $395.04 million. Following these results, Integra LifeSciences updated its full-year revenue guidance due to increased visibility, while maintaining its earnings per share forecast. Despite a weaker third-quarter target, the company remains optimistic about its annual performance.

In light of these developments, JMP Securities reiterated its Market Outperform rating for Integra LifeSciences, maintaining a price target of $25.00. This reflects confidence in the company’s ability to meet its financial goals. The analyst firm noted that the second-quarter sales exceeded management’s expectations, highlighting the company’s robust performance. These recent developments underscore Integra LifeSciences’ strong market position and positive outlook from analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.